## GEHC: GE HealthCare Technologies Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 4.3% in lower entry zone (4.0-10.0%), top quartile (86th pct) cross-sectional ranking. Caution: MRS_5 (-1.0%) diverging from MRS_20, watch for reversal. Outperforming sector by 2.9%. Caution: declining volume (52% of avg), momentum weakening (-1.9% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($75.00)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 10, Bearish: 0)

**1. GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025**
- Source: Business Wire | 20251130T150611 | Bullish | Relevance: 99%
- GE HealthCare is showcasing transformative innovations at RSNA 2025, building on over a century of medical technology advancements. The company has invested more than $3 billion in R&D since 2022 to develop AI-enabled and cloud-based solutions, including new CT, MRI, mammography, and ultrasound technologies, alongside advanced radiopharmaceuticals, aiming to address critical challenges in radiology departments. These innovations aim to improve diagnostic precision, enhance operational efficiency, and advance personalized patient care.

**2. GE HealthCare to showcase innovations at RSNA 2025 meeting**
- Source: TipRanks | 20251130T183622 | Bullish | Relevance: 99%
- GE HealthCare (GEHC) announced its plans to showcase significant innovations at the Radiological Society of North Americaâ€™s (RSNA) 2025 Annual Meeting. The featured innovations will include Photonova Spectra, next-gen SIGNA MRI technology, Pristina Recon DL, Vivid Pioneer, Flyrcado injection, and Definium Pace Select, highlighting the company's commitment to advancing precision care.

**3. Fitch Rates GE Healthcare's Senior Unsecured Notes 'BBB'**
- Source: TradingView | 20251201T142617 | Bullish | Relevance: 99%
- Fitch Ratings has assigned 'BBB' ratings to GE HealthCare Technologies Inc.'s senior unsecured notes, with proceeds primarily intended for the acquisition of Intelerad Medical Systems, Inc. The rating is supported by GEHC's solid standalone operating performance, consistent free cash flow generation, and leading market position in the medical imaging space, despite geopolitical risks and significant pension benefit obligations. Fitch forecasts revenue growth and margin expansion in the coming years, driven by innovation and strategic acquisitions.

**4. GE HealthCare unveils next-generation SIGNA MRI technology, aiming to boost efficiency, enhance patient experience, and advance sustainability**
- Source: Lelezard | 20251130T090500 | Bullish | Relevance: 98%
- GE HealthCare has unveiled its next-generation SIGNA MRI technology, including SIGNA Bolt, SIGNA Sprint with Freelium, and SIGNA One, aiming to improve efficiency, patient experience, and sustainability. These new systems feature AI-powered workflows, significantly reduced helium usage, and advanced capabilities designed to address current challenges in healthcare imaging. The technologies are currently pending 510(k) clearance from the U.S. FDA, with the goal of making MRI more intuitive, efficient, and impactful in everyday care.

**5. GE HealthCare builds on a century of innovation to shape the future of radiology at RSNA 2025**
- Source: The AI Journal | 20251130T145119 | Bullish | Relevance: 98%
- GE HealthCare (Nasdaq: GEHC) will showcase over 40 transformative innovations at RSNA 2025, building on more than a century of leadership in medical imaging. The company has invested over $3 billion in R&D since 2022 to address pressing healthcare challenges such as staff shortages and rising demand, leveraging AI and cloud-based solutions to enhance precision care. Key product unveilings include new photon counting CT systems, next-gen SIGNA MRI technology, advanced mammography, and AI-enabled workflow platforms, reflecting their commitment to innovation and clinician empowerment.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-21 | BTIG | $87 | $87 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-21 | BTIG | reit | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.2%)
- Blackrock Inc.: 8.0% (+1.9%)
- Dodge & Cox Inc.: 6.0% (+16.8%)
- Capital Research Glo: 5.5% (+25.0%)
- State Street Corpora: 4.3% (-0.1%)

### Key Risks

1. Valuation stretched: PEG 3.5x requires aggressive growth execution.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.50 signals overvaluation risk, limited margin of safety. Quality metrics strong (ROE 24%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.6B |
| Beta | 1.24 |
| 52W Range | $57.65 - $94.80 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.50 |
| Forward P/E | 16.1 |
| Current P/E | 17.4 |
| YoY Growth | 8.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.2% to 4.3% (-1.9% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 86th percentile. MRS_5 (-1.0%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 5.4% shows strong absolute momentum above own 20MA. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.78), confirming momentum. Volume at 52% of 20MA suggests lack of conviction.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.28% (CS: 86) | Strong |
| RSI_14 | 61.2 | Neutral |
| MACD Histogram | 0.78 | Bullish |
| vs SMA20 | 1.054x | Above |
| vs SMA50 | 1.056x | Above |
| vs SMA200 | 1.058x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $79.24
- **Stop Loss:** $75.00 (5.4% risk)
- **Target:** $85.60 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 176
- **Position Value:** $13,946.24
- **Portfolio %:** 13.95%
- **Risk Dollars:** $750.00
- **Risk Per Trade:** 0.75%
- **Modifiers:** L1 100% | L2 75% | Combined 0.75x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | WEAKENING (Zone B) | 0.75x |

### Earnings

**Next:** 2026-02-12 (Est: $1.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.05 | $1.07 | +2.2% |
| 2025Q2 | $0.92 | $1.06 | +15.4% |
| 2025Q1 | $0.91 | $1.01 | +10.6% |
| 2024Q4 | $1.26 | $1.45 | +14.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*